News | June 13, 2023
Pfizer and GSK to battle for share of new RSV vaccine market, says GlobalData
Pfizer is likely to show GSK significant competition
Pfizer is likely to show GSK significant competition
Authorisation will help protect adults 60 years of age and older in 30 European countries* from RSV disease for the first time
These initiatives aim to improve access to healthcare for rare disease patients
Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
Venkat Nageswar Chalasani has been appointed as an Independent Director of Apitoria Pharma with effect from April 4, 2023
States advised to undertake mock drills to ensure operational readiness of Hospital Infrastructure including Oxygen Cylinders, PSA plants, ventilators and human resources
The Indian government will float a global tender in April 2023 to procure HPV vaccines.
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
Subscribe To Our Newsletter & Stay Updated
